论文部分内容阅读
目的观察甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎的疗效与安全性。方法选取医院收治的支原体肺炎(RMPP)患儿68例为研究对象,随机分为对照组和观察组,每组34例。对照组采用阿奇霉素治疗,观察组采用甲泼尼龙联合阿奇霉素治疗,观察2组临床疗效、相关时间指标、CRP水平变化及不良反应。结果观察组总有效率为94.1%,高于对照组的85.3%(P<0.05)。观察组咳嗽消失时间、退热时间、住院时间、肺阴影消失时间,均短于对照组(P<0.01)。治疗1周后,观察组CRP水平下降,优于对照组(P<0.01);2组患者不良反应比较,差异无统计学意义(P>0.05)。结论小儿难治性支原体肺炎采用甲泼尼龙联合阿奇霉素治疗,疗效显著,缩短住院时间,且不良反应少,值得临床推广应用。
Objective To observe the efficacy and safety of methylprednisolone and azithromycin in the treatment of refractory mycoplasma pneumonia in children. Methods Sixty-eight children with mycoplasma pneumonia (RMPP) admitted to the hospital were selected as the research object and randomly divided into control group and observation group, 34 cases in each group. The control group was treated with azithromycin. The observation group was treated with methylprednisolone combined with azithromycin. The clinical curative effect, relevant time index, CRP level changes and adverse reactions in the observation group were observed. Results The total effective rate in the observation group was 94.1%, which was higher than that in the control group (85.3%, P <0.05). Observation group cough disappear time, antipyretic time, hospital stay, lung shadow disappear time, were shorter than the control group (P <0.01). After one week of treatment, the level of CRP in the observation group was significantly lower than that in the control group (P <0.01). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Pediatric refractory mycoplasma pneumonia is treated with methylprednisolone combined with azithromycin, with significant curative effect, shortened hospitalization time and less adverse reactions, which is worthy of clinical application.